Compare Align Technology, Inc. (ALGN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Align Technology, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while IDEXX Laboratories, Inc. trades at $565 (market cap $44.46B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.5× Align Technology, Inc.'s market cap, and Align Technology, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | IDXX | |
|---|---|---|
Market Cap | $12.86B | $44.46B |
Sector | Health | Health |
52-Week High | $207.19 | $766.68 |
52-Week Low | $124.88 | $514.61 |
Enterprise Value | $11.92B | $45.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
IDXX trades at $563.57, up 0.89% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.47 surpassing estimates. Revenue grew to $4.3B in 2025, with a robust net income margin of 24.63%. Analyst consensus is bullish with a $645 price target. Recent news highlights innovation in veterinary diagnostics and AI integration.
The outlook remains positive driven by earnings growth and market leadership, though high valuation multiples pose a risk. Key catalysts include upcoming Q2 2026 results and continued demand in pet healthcare. Risks involve competitive pressures and macroeconomic sensitivity. The stock offers growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
